Wedbush increased its price target for Scholar Rock to $64 from $58 and kept an "Outperform" rating ahead of the FDA's September 30 decision on Scholar Rock's investigational SMA drug, apitegromab. This drug could be the first muscle-targeted therapy for spinal muscular atrophy, showing promise as a novel treatment by inhibiting myostatin to promote muscle growth. Scholar Rock has made regulatory and manufacturing progress, including updating its biologics license application and securing an alternative manufacturing facility. The FDA decision is a key catalyst for the stock, which currently trades near $56 with a market cap of about $6.69 billion.
IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, will conduct a 1-for-30 reverse stock split on August 27, 2026. This move aims to increase its share price, currently at $0.11, to meet the Nasdaq Capital Market's minimum...
Buckle, Inc. reported strong Q2 earnings with an EPS of $0.87, surpassing analyst estimates of $0.81, and revenue of $319.82 million, slightly above expectations. The company saw a 4.6% increase in net sales, driven by growth in both comparable-store...
KE Holdings Inc. reported Q2 2026 earnings with an EPS of $0.42, surpassing the $0.31 consensus estimate. Although revenue declined 5.7% year-over-year to about $3.60 billion, the company doubled its net income thanks to effective cost controls and o...
Tesla reported a 26% year-over-year revenue increase despite a 23% drop in its stock price this year. The company remains a leader in the electric vehicle market, supported by growth opportunities in robotaxi, robotics, and AI sectors. However, Tesla...
Harbor Diversified likely holds about $3.67 per share in net cash and securities after selling off Air Wisconsin and aviation assets. Despite this, its stock trades at a 50% discount to net cash, reflecting investor uncertainty about how the company ...
